Article
Plasmodium vivax mdr1 genotypes in isolates from successfully cured patients living in endemic and non-endemic Brazilian areas
Registro en:
GOMES, Larissa Rodrigues; et al. Plasmodium vivax mdr1 genotypes in isolates from successfully cured patients living in endemic and non‑endemic Brazilian areas. Malaria Journal, v.15, n.96, 5p, 2016.
1475-2875
10.1186/s12936-016-1141-9
Autor
Gomes, Larissa Rodrigues
Oliveira, Natália Ketrin Almeida de
Lavigne, Aline Rosa de
Lima, Suelen Rezende Félix de
Costa, Anielle de Pina
Brasil, Patrícia
Daniel-Ribeiro, Cláudio Tadeu
Ménard, Didier
Cruz, Maria de Fátima Ferreira da
Resumen
Plasmodium vivax is the most widely distributed species causing the highest number of malaria cases in the world. In Brazil, P. vivax is responsible for approximately 84 % of reported cases. In the absence of a vaccine, control strategies are based on the management of cases through rapid diagnosis and adequate treatment, in addition to vector control measures. The approaches used to investigate P. vivax resistance to chloroquine (CQ) were exclusively in vivo studies because of the difficulty in keeping parasites in continuous in vitro culture. In view of the limitations related to follow-up of patients and to assessing the plasma dosage of CQ and its metabolites, an alternative approach to monitor chemo-resistance (QR) is to use molecular markers. Single nucleotide polymorphisms (SNPs) in the multidrug resistance gene pvmdr1 are putative determinants of CQ resistance (CQR), but such SNPs in P. vivax isolates from patients with good response to treatment should be further explored. The aim of this study is to investigate the mutations in the gene, supposedly associated to QR, in P. vivax isolates from successfully cured patients, living in Brazilian endemic and non-endemic areas.